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Summary
 
In studying the subdominant status of two cysteine-containing influenza virus nuclear protein
(NP) determinants (NP
 
39–47
 
 and NP
 
218–226
 
) restricted by H-2K
 
d
 
, we found that the antigenicity
of synthetic peptides was enhanced 10–100-fold by treatment with reducing agents, despite the
fact that the affinity for K
 
d
 
 was not enhanced. Reducing agents also markedly enhanced the im-
munogenicity of cysteine-containing peptides, as measured by propagation of long-term T cell
lines in vitro. Similar enhancing effects were obtained by substituting cysteine with alanine or
serine in the synthetic peptides, demonstrating that sulfhydryl modification of cysteine is re-
sponsible for the impaired antigenicity and immunogenicity of NP
 
39–47
 
 and NP
 
218–226
 
. We
found similar effects for two widely studied, cysteine-containing peptides from lymphocytic
choriomeningitis virus. The major modifications of cysteine-containing synthetic peptides are
cysteinylation and dimerization occurring through cysteine residues. We demonstrate that both
of these modifications occur in cells synthesizing a cytosolic NP
 
218–226
 
 minigene product and,
further, that T cells specific for cysteinylated NP
 
218–226
 
 are induced by influenza virus infection
in mice, demonstrating that this modification occurs in vivo. These findings demonstrate that
posttranslational modifications affect the immunogenicity and antigenicity of cysteine-contain-
ing viral peptides and that this must be considered in studying the status of such peptides in im-
munodominance hierarchies.
Key words: antigen processing • cysteine/immunology • major histocompatibility
complex/immunology • viral vaccines/immunology • peptides/immunology
 
C
 
D8
 
1
 
 T cells (T
 
CD8
 
1
 
) recognize peptides, usually of 8–10
residues, complexed to MHC class I molecules. The
peptide binding site is formed by class I heavy chains,
which are encoded by genes that are highly polymorphic in
most species. Most of the variability between heavy chain
alleles resides in residues located in the peptide binding site.
As a result, each class I allele presents a unique spectrum of
peptides to the immune system (1). Although the rules that
govern peptide binding to different alleles are far from sim-
ple, most peptides recovered from a given allele conform to
a simple motif dictated largely by the nature of two to three
“pockets” present at the bottom of the binding groove (2).
Using these motifs, it is possible to identify upwards of 90%
of peptides in a given sequence that could potentially bind
to a given allele with biologically significant affinity. Syn-
thetic peptides corresponding to these sequences can be
tested for immunogenicity, antigenicity, and binding to class I
molecules.
Although this method is capable of identifying antigenic
regions of proteins, it remains a considerable challenge to
establish the precise structure of the naturally processed de-
terminant. As a first step, the chromatographic properties of
synthetic and naturally processed peptides recovered from
class I molecules can be compared by HPLC. Coelution in-
dicates a close structural relationship, but the exact struc-
ture of the naturally processed peptide can only be estab-
lished by mass spectroscopy (3). This is sufficiently difficult
to preclude publication of mass spectroscopic analysis of
viral peptides to date.
The possibilities for surprises in the structure of naturally
processed peptides have been amply documented by Mead-
ows et al. (4), who have identified peptides with a number
of posttranslational modifications. Of direct relevance to the
present study, naturally processed peptides with cysteiny-
lated cysteine residue were identified, as were T
 
CD8
 
1 
 
that
required this modification for activation (4). 
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Cysteine Modification of Viral Peptides
 
Due to its free SH group, cysteine is the most chemically
reactive of the 20 common amino acids under physiologi-
cal conditions. Cysteine is the second least frequent residue
in proteins, representing 1.7% of the residues present in eu-
karyotic proteins. Its occurrence in antigenic peptides is
consistent with random usage, being present in 14% of 384
class I ligands (1) (predicted frequency in nonamers is 9
 
0.83
 
 
 
5
 
14%). The frequency of cysteine-containing determinants
is expected to be even higher in cysteine-rich proteins,
such as Her2/Neu, a promising target for tumor immuno-
therapy (5). In this study, we show that modification of
cysteine residues in naturally processed and synthetic pep-
tides has profound negative and positive effects on the anti-
genicity and immunogenicity of viral determinants.
 
Materials and Methods
 
Cell Culture.
 
All media, including cystine-containing and
cystine/methionine-free DMEM, were purchased from Bio-
fluids, Inc. The mastocytoma cell line P815 (H-2
 
d
 
) and the thy-
moma cell line EL-4 (H-2
 
b
 
) were maintained in DMEM contain-
ing 10% fetal bovine serum (FBS),
 
1
 
 5 
 
3
 
 10
 
2
 
5 
 
M 
 
b
 
-ME, antibiotics,
and 2 mM glutamine (DME-10). K
 
d
 
-transfected T2 (T2-K
 
d
 
) and
RMA-S (RMA-S/K
 
d
 
) cells were cultured in RPMI 1640 contain-
ing 10% FBS and the above supplements (RP-10). CTL stimula-
tion and maintenance were performed in RP-10 medium contain-
ing 10 U/ml of recombinant human IL-2. In some assays, cells
were incubated with IMDM supplemented with 10% FBS (I-10).
 
CTL Priming In Vivo and Assay.
 
8–10-wk-old female BALB/c
mice or C57BL/6 mice were injected intraperitoneally with 1 ml
of a 1:10 dilution of chicken egg allantoic fluid containing influ-
enza A virus Puerto Rico/8/34 (PR8) or intravenously with 10
 
7
 
PFU of lymphocytic choriomeningitis virus (LCMV) WE strain.
Splenocytes were stimulated with peptide-pulsed APCs for 7 d in
vitro at least 3 wk after virus priming. Cells were stimulated in
RP-10 with 10 U/ml IL-2 in 6-well plates. In brief, 3 
 
3 
 
10
 
7
 
 sple-
nocytes were stimulated with 6 
 
3
 
 10
 
5
 
 virus-infected or peptide-
pulsed (1 nM) APC, which were irradiated with 200 Gy before
addition to cultures. After 4 d, live cells were recovered via a
Ficoll–Hypaque gradient and recultured with fresh IL-2–contain-
ing medium. CTL activities were tested after 7 d in standard 
 
51
 
Cr-
release microcytotoxicity assays. In some cases, short-term CTL
lines were used, which were restimulated weekly for up to 5–6 wk.
 
Virus Infections.
 
For PR8 infection, log-phase cells were har-
vested and washed in serum-free Autopow MEM (Life Technol-
ogies), adjusted to pH 6.6, and resuspended in 200 
 
m
 
l of the same
medium containing 100 
 
m
 
l PR8-containing allantoic fluid per
10
 
6
 
 cells. For vaccinia virus (VV) infection, cells were infected at
a multiplicity of infection of 10 in basal salt solution supple-
mented with 0.1% BSA (wt/vol) at a concentration of 5 
 
3
 
 10
 
6
 
cells/ml. Cells were incubated for 1 h at 37
 
8
 
C in a water bath be-
fore 2 ml of prewarmed complete medium was added. Cells were
then further incubated for 1–2 h before 
 
51
 
Cr labeling, unless indi-
cated otherwise.
 
Peptides, Binding Assays, and Flow Cytometry.
 
All peptides were
synthesized, HPLC-purified, and analyzed by mass spectrometry
by the Biologic Resource Branch, National Institute of Allergy and
 
Infectious Diseases. Peptides were dissolved at 1 mM in DMSO
and stored at 
 
2
 
20
 
8
 
C unless otherwise indicated. For analytical pur-
poses, peptide masses were determined by matrix assisted laser de-
sorption ionization with time of flight detection (MALDI-TOF)
using a Hewlett Packard mass spectrometer (model G2025A) and
cyano-4-hydroxycinnamic acid as the matrix. Peptide binding to
live cells was determined by protection of class I molecules to melt-
ing (6). In brief, T2-K
 
d
 
 cells were cultured for 14–16 h at 26
 
8
 
C.
Synthetic peptides, diluted in FBS-free DME in the presence or
absence of tris (2-carboxyethyl) phosphine hydrochloride (TCEP;
Pierce Chemical Co.) as indicated, were added to cells, which
were incubated at 37
 
8
 
C for 2 h to denature K
 
d
 
 molecules not stabi-
lized by peptide binding. Cells were then washed and stained with
fluorescein-conjugated SF1-1.1 (PharMingen). Live cells were
gated based on scattering and exclusion of ethidium homodimer
(Molecular Probes, Inc.) present at 5 
 
m
 
g/ml for 5 min before the
last wash. For each histogram, 10,000–20,000 cells were counted
on a Becton Dickinson FACScan™, and live cells were analyzed
using CELLQuest™ software (Becton Dickinson).
 
Extraction of Cellular Peptides and Fractionation by Reversed-phase
HPLC (RP-HPLC).
 
Natural peptides were recovered and ana-
lyzed as previously described (7). In brief, cultures of P815 cells
were expanded in roller bottles. 5 
 
3
 
 10
 
8
 
–10
 
9
 
 cells were infected
as described above and incubated for 6 h at 37
 
8
 
C before being
pelleted, washed twice in PBS, lysed with ice-cold 0.33% TFA/
H
 
2
 
O, and further disrupted using a TenBroek tissue homogenizer
on ice. At this stage, synthetic peptides were added to uninfected
P815 cells as control. Lysates were sonicated and centrifuged at
10,000 
 
g
 
 for 30 min, and the supernatants were passed through a
3K cutoff filter (Macrosep™ filtron 3K; Pall Filtron Corp.). Sam-
ples were dried to a volume 
 
.
 
400 
 
m
 
l using a SpeedVac (Savant
Instruments, Inc.) and fractionated on a C18 column (Deltapack;
Waters) at 1 ml/min on TFA/acetonitrile gradient (7). Either
0.25- or 1-ml fractions were collected.
 
Microcytotoxicity Assay.
 
Generally, 10
 
6
 
 target cells were labeled
with 100 
 
m
 
Ci of Na
 
51
 
CrO
 
4
 
 (Dupont) in minimum volume of
medium at 37
 
8
 
C for 60 min. For some experiments, RMA-S/K
 
d
 
cells that had been cultured for 12–14 h at 26
 
8
 
C were labeled at
26
 
8
 
C for the same time period. After two washes, 10
 
4
 
 cells were
aliquoted into round-bottom, 96-well plates containing serial di-
lutions of effector T
 
CD8
 
1
 
. For testing HPLC fractions, target cells
in 50 
 
m
 
l of either PBS or FCS-free medium were exposed to 5 
 
m
 
l
of fractions for 30 min at 26
 
8
 
C before T
 
CD8
 
1
 
 were added. In
some experiments, TCEP was freshly dissolved in H
 
2
 
O and used
at 200 
 
m
 
M, both at peptide-pulsing and microcytotoxicity assay
stages. The radioactivity in supernatants collected after 4–6-h in-
cubation at 37
 
8
 
C was determined using a gamma
 
 
 
counter. The
percent specific release was then determined as: % specific release 
 
5
 
(CTL-induced release 
 
2
 
 spontaneous release)/(release by deter-
gent 
 
2
 
 spontaneous release) 
 
3
 
 100.
 
Results
 
T
 
CD8
 
1
 
 Specific for Cysteine-containing Determinants Apparently
Require More Peptide–Class I Complexes.
 
We previously re-
ported that in K
 
d
 
-restricted responses to PR8 influenza
virus nuclear protein (NP), NP
 
147–155
 
 is the immunodomi-
nant determinant, with NP
 
39–47
 
 and NP
 
218–226
 
 exhibiting
subdominant status (8). This hierarchy is not accounted for
by peptide affinity, as NP
 
147–155
 
 binds to K
 
d
 
 with the lowest
efficiency, as determined by a K
 
d
 
 “melting” assay per-
formed either with RMA-S cells expressing K
 
d
 
 from a
 
1
 
Abbreviations used in this paper:
 
 ER, endoplasmic reticulum;
 
 
 
FBS, fetal bo-
vine serum; LCMV, lymphocytic choriomeningitis virus; NP, nuclear
protein; RP-HPLC, reversed-phase HPLC; VV, vaccinia virus. 
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transfected gene (data not shown) or T2 cells (8). We ini-
tially focused on T
 
CD8
 
1
 
 avidity to explain the immu-
nodominance of NP
 
147–155
 
, as 10-fold less synthetic NP
 
147–155
 
was usually required to sensitize target cells for lysis by
T
 
CD8
 
1
 
 lines raised to the individual peptides under condi-
tions similar to those used for the peptide binding assay
(Fig. 1 B). This was observed using either short- or long-
term lines stimulated in vitro by synthetic peptides derived
from animals immunized either with PR8 or rVV express-
ing NP or cytosolic or endoplasmic reticulum (ER)-tar-
geted minigene product versions of the determinants. Tak-
ing into account the lower efficiency of NP
 
147–155
 
 binding to
K
 
d
 
, the data in Fig. 1 suggest that 
 
,
 
10% of K
 
d
 
-NP
 
147–155
 
complexes are required for T
 
CD8
 
1
 
 triggering relative to K
 
d
 
complexed to either of the subdominant determinants.
Several findings, however, suggested that matters might be
a bit more complicated. Unlike NP
 
147–155
 
, the dose–response
curves of NP
 
39–47
 
 and NP
 
218–226
 
 varied considerably between
experiments, depending in part on the manner in which the
assay was executed. We also experienced difficulties in stim-
ulating and maintaining T
 
CD8
 
1
 
 lines to these subdominant
determinants, often observing slower growth after restimula-
tion and morphological abnormalities of the cells, which
were frequently larger than T
 
CD8
 
1
 
 specific for NP
 
147–155
 
.
This was not strictly related to the subdominant status of
these determinants, as T
 
CD8
 
1
 
 specific for other subdominant
determinants behaved similarly to NP
 
147–155-specific TCD81.
A property shared by NP218–226 and NP39–47 is the pres-
ence of cysteine (Table I). The report by Meadows et al.
(4) demonstrating the dramatic effects of sulfhydryl modifi-
cation of cysteine-containing residues on TCD81 recogni-
tion prompted us to examine possible effects of cysteine
modification on NP39–47 and NP218–226 binding and antige-
nicity. We first studied the properties of synthetic peptides
in which cysteine is replaced by serine or alanine (the most
conservative substitutions). For NP39–47, the cysteine®
serine substitution had no significant effect on peptide
binding, whereas the cysteine®alanine substitution increased
peptide potency by z10-fold (Fig. 2 A). For NP218–226,
either substitution reduced peptide potency in stabilizing
Kd molecules by z10-fold (Fig. 2 B). Each of the substitu-
tions resulted in large increases in antigenicity relative to
the wild-type peptides (Fig. 2, C and D). For NP218–226, the
substituted peptides were 1,000–10,000-fold more antigenic
on a per-complex basis (assuming that complex formation
Figure 1. Antigenicity of synthetic peptides corresponding to domi-
nant and subdominant determinants. (A) T2-Kd cells were cultured for 14 h
at 268C and added to the wells containing synthetic peptides at the indi-
cated concentrations. The samples were immediately shifted to 378C and
incubated for 2 h to denature Kd molecules lacking peptides and then
stained with a fluorescein-conjugated anti-Kd mAb. The mean channel
fluorescence (MCF) of viable cells was determined by flow cytometry.
(B) Splenocytes from PR8-primed animals stimulated in vitro for 7 d
with synthetic peptides corresponding to NP39–47, NP147–155, or NP218–226
were tested in a microcytotoxicity assay for their ability to lyse 51Cr-
labeled P815 target cells incubated in I-10 with synthetic peptides at the
indicated concentrations.
Table I. Properties of Peptides Used in This Study
Peptide Sequence
HPLC elution
time
min
NP39–47 FYIQMCTEL
NP147–155 TYQRTRALV
NP218–226 AYERMCNIL 25
CysNP218–226 AYERMCNIL
:
C2 7
dimNP218–226 AYERMCNIL
:
AYERMCNIL 29
GP33–41 KAVYNFATC
GP276–286 SGVENPGGYCL
NP396–404 FQPQNGQFI
GP, glycoprotein; :, disulfide bond.
Figure 2. Binding and antigenicity of synthetic peptides. A and B show
data from the Kd-melting experiment displayed in Fig. 1 A. In this case,
data for wild-type NP39–47 and NP218–226 are replotted with the substituted
peptides. In C and D, TCD81 specific for NP39–47 or NP218–226 were tested
in a microcytotoxicity assay for their ability to lyse 51Cr-labeled P815 tar-
get cells incubated in I-10 in the presence of the synthetic peptides at the
indicated concentrations.1760 Cysteine Modification of Viral Peptides
at the endpoint of peptide titrations is proportional to pep-
tide binding efficiency determined by the melting assay).
These findings prompted us to study the effects of sulf-
hydryl modification on the antigenicity of NP39–47 and
NP218–226. In most experiments described below, the two
peptides were studied in parallel. Because the results were
highly similar, only results with NP218–226 are shown for the
sake of clarity and simplicity.
Reduction of Cysteine Enhances the Antigenicity of Cysteine-
containing Viral Peptides. Cysteine readily forms disulfide
bonds at neutral or slightly basic pH in the presence of O2
at atmospheric tension, and oxidation to the disulfide is
stimulated by trace amounts of iron salts that are present in
tissue culture media. The disulfide can be reduced to the
original thiol form by exposure to reducing agents. To de-
termine whether disulfide formation affected peptide anti-
genicity, synthetic NP218–226 was added to cells in the pres-
ence of dithiothreitol or TCEP, and cells were tested for
lysis by NP218–226-specific TCD81. Either of these reducing
agents increased peptide potency by z10-fold (Fig. 3 A).
Reducing agents did not affect the potency of noncysteine-
containing peptides, including NP147–155 (Fig. 3 B), an
LCMV peptide (described below), or the cysteine®serine-
or cysteine®alanine-substituted NP39–47 peptides (not
shown). Enhancement of cysteine peptide recognition is, as
expected, dependent on the concentration of reducing
agent, with TCEP being more effective on a molar basis
than dithiothreitol (not shown). The optimal concentration
for TCEP was 200 mM (used in additional experiments), as
higher concentrations (1 mM) sometimes increased sponta-
neous release values in 51Cr-release assays. The effect of
TCEP on NP218–226 antigenicity is particularly impressive
when considered in view of the 100–1,000-fold decrease in
peptide binding to Kd in the presence of TCEP (described
below).
In additional experiments, we found that inclusion of re-
ducing agents in the media used to stimulate and propagate
TCD81 specific for NP218–226 or NP39–47 greatly enhanced
their growth and altered their appearance, to the extent
that these TCD81 were indistinguishable from TCD81 raised
to NP147–155 or other immunodominant determinants.
These findings indicated that sulfhydryl modification can
have major effects on the antigenicity and immunogenicity
of synthetic peptides, effects that can lead to erroneous con-
clusions regarding the nature of their interactions with class I
molecules, the affinity of TCD81 specific for the peptide, and
the growth characteristics of the cells. To broaden these
findings, we examined the effect of reducing agents on the in
vitro antigenicity of three oft-studied, Db-restricted determi-
nants from LCMV: two containing cysteine (GP33–41 and
GP276–284) and a control determinant lacking cysteine
(NP396–404) (Table I). As with the influenza virus determinants,
the cysteine-containing peptides were recognized 10–100-fold
less efficiently than the cysteine-free peptide in the absence
of reducing agent (Fig. 4, A and B), whereas TCEP had no
affect on the antigenicity of NP396–404 (Fig. 4 C).
Based on these findings, it is clear that sulfhydryl modifi-
cation of cysteine-containing synthetic peptides can have
major effects on TCD81 growth and target cell recognition
that must be taken into consideration in investigating the
biological properties of the corresponding naturally pro-
duced determinants and the TCD81 they induce.
Nature of Thiol-modifying Agents Affects NP218–226. We
turned our attention to why reducing agents enhance the
antigenicity of synthetic NP218–226. The major possibilities
were reduction of disulfide-linked peptide dimers and re-
duction of disulfide-bound species derived from culture
media. The most abundant sulfhydryl-containing compound
present in DMEM is cystine (cysteine–cysteine dimers). To
determine whether NP218–226 becomes cysteinylated in
DMEM, freshly dissolved NP218–226 was incubated in nor-
mal or cystine-free DMEM for 2 h. Peptides present in
media were then separated by RP-HPLC, and the masses
in peptide-containing fractions were determined by mass
spectroscopy (Fig. 5). After incubation in cysteine-free me-
dia, the only modification detected was a small amount of
dimerization (Fig. 5 B). By contrast, in cysteine-containing
media, most of the monomer was converted to a separate
eluting form representing cysteinylated peptide (Fig. 5 C).
This fraction also contained a minor species with an addi-
tional mass of 16 daltons that probably represents oxidation
of the neighboring methionine residue in the peptide.
The effect of cysteinylation on NP218–226 antigenicity was
Figure 3. Effects of reducing agents on the antigenicity and Kd binding
of synthetic NP218–226. Synthetic peptides were diluted in I-10 with or
without 200 mM of the indicated reducing agents and added to assay wells
containing 51Cr-labeled target cells and TCD81 specific for NP218–226 (A) or
NP147–155 (B), and lysis was determined by microcytotoxicity assay.1761 Chen et al.
examined by measuring the Kd binding and antigenicity of
an unmodified preparation of NP218–226 incubated for 2 h in
cystine-containing DMEM with or without TCEP before
addition to cells. As seen in Fig. 6 A, the resulting cysteiny-
lation was associated with an z10-fold increase in rescuing
Kd molecules from melting and an z10,000-fold decrease
in capacity to sensitize target cells for lysis by TCD81 induced
by APCs pulsed with unmodified NP218–226.
We also examined the effect of NP218–226 dimerization on
antigenicity and Kd binding. Analysis of various stocks by
RP-HPLC in conjunction with mass spectrometry revealed
that a 1-yr-old stock of peptide in DMSO was .95% dimer-
ized (Fig. 5 D). Using this stock as an NP218–226 dimer source,
we investigated the effect of 2-h incubation at room temper-
ature in cystine-free or cystine-containing DMEM. NP218–226
dimers were stable under these conditions (Fig. 5, E and F).
Having identified a source of dimers and demonstrated the
stability of dimers in DMEM, we could examine the Kd
binding and antigenicity of dimers (Fig. 6), which revealed
that dimers behaved similarly to cysteinylated NP218–226.
We draw two conclusions from these findings. First, cys-
teinylation and dimerization of NP218–226 is associated with
enhanced Kd binding yet greatly reduced antigenicity, using
TCD81 restimulated by the reduced peptide. Second, in nor-
mal DMEM, cysteinylation occurs preferentially to peptide
dimerization, even when NP218–226 is present at relatively
high concentrations. As a second-order reaction, dimeriza-
tion should be greatly disfavored at decreasing peptide con-
centrations, whereas cysteinylation continues at a first-order
reaction rate. Therefore, cysteinylation is probably the major
process for modifying cysteine-containing peptides at the
concentrations used in Kd-binding and 51Cr-release assays.
Cysteinylated NP218–226 Is Produced by Virus-infected Cells.
Given the potential for cysteine modification in vitro, we ex-
amined whether NP218–226 produced by PR8-infected cells
was modified in vivo. Low Mr peptides present in acid extracts
from whole cells were fractionated by RP-HPLC and tested
for their abilities to sensitize target cells for lysis by TCD81
raised to reduced NP218–226. TCEP was added to the fractions
to reveal the presence of SH-modified forms of peptides ren-
dered nonantigenic by the modification. As shown in Fig.
Figure 4. The antigenicity of Db-restricted synthetic peptides corresponding to LCMV determinants is enhanced by reducing agents. Splenocytes from
C57BL/6 mice infected 3 wk previously with LCMV were stimulated in vitro by incubation for 7 d with synthetic peptide–pulsed EL-4 cells and restim-
ulated in the same manner for an additional 5 d. Synthetic peptides were diluted in PBS in the presence or absence of 200 mM TCEP and added to assay
wells containing LCMV-specific TCD81 and 51Cr-labeled EL-4 cells, and lysis was determined by microcytotoxicity assay in I-10.
Figure 5. RP-HPLC mass spectrometric characterization of syn-
thetic NP218–226. 10 mmol of NP218–226, either a freshly made stock in
PBS (A) or 1-yr stock in DMSO (D), were added to 300 ml of cystine-
free or cystine-containing DME, incubated for 2 h at room tempera-
ture, and analyzed by RP-HPLC. The masses of material in eluting
peaks were determined by MALDI-TOF, revealing that cysteinylated
NP218–226 elutes at 25 min, unmodified NP218–226 at 27 min, and
dimeric NP218–226 at 29 min. A, in PBS 1 TCEP; B, monomer in cys-
tine-free medium; C, monomer in cystine-containing medium; D, in
DMSO; E, dimer in cystine-free medium; F, dimer in cystine-contain-
ing medium.1762 Cysteine Modification of Viral Peptides
7 A, antigenic peptides were recovered in fractions eluting
from 25–27 min, matching the elution times of cysteinylated
(25 min) and unmodified (27 min) NP218–226. No activity
was present in the 29-min fraction, where dimeric NP218–226
elutes. The amounts of peptide recovered were well below
that required for saturation (peak lysis of column fraction of
40% versus 70% with a saturating amount of synthetic peptide;
Fig. 7 A, top right), suggesting that a considerable fraction of
NP218–226 recovered from PR8-infected cells is cysteinylated.
Cysteinylation of NP218–226 might have occurred artefac-
tually during the extraction process. To examine this pos-
sibility, cell homogenates were doped with synthetic,
unmodified NP218–226 and then processed identically to
virus-infected cells (note that in this and subsequent experi-
ments, to increase the chromatographic resolution, fraction
size was reduced from 1 ml to 0.25 ml) (Fig. 7 B). In this
case, ,1% of the antigenic activity (as determined by titrat-
ing fractions; data not shown) was recovered in the cysteiny-
lated form. In this experiment, peptides were tested in the
presence or absence of TCEP. Even unmodified NP218–226
required TCEP treatment, which we attribute to rapid pep-
tide cysteinylation during target cell sensitization.
To examine the maximal potential for posttranslational
modification of NP218–226, we infected cells with an rVV
(VV-NP218–226) that expresses the peptide in the cytosol as a
minigene product (with NH2-terminal methionine to en-
able translation initiation). As reported previously (7–9),
this greatly enhances the number of peptide–class I com-
plexes generated by cells. RP-HPLC fractionation from
minigene-expressing cells revealed the presence of material
coeluting with unmodified NP218–226, as well as cysteinylated
peptide (Fig. 7 C). For the first time, dimeric peptide was
also detected. These activities cannot be attributed to me-
thionine-extended NP218–226, which, for each form, elutes
slightly later than NP218–226 (data not shown). Titration of
the antigenic activities in the fractions (not shown) revealed a
ratio of unmodified/cysteinylated/dimeric forms of z6:3:1.
In an additional experiment (data not shown), we exam-
ined the Kd dependence of NP218–226 recovery in HPLC
fractions after VV-NP218–226 by using L929 cells and L929
cells expressing Kd from a transgene. Peptides correspond-
Figure 6. Binding and antigenicity of cysteine-modified NP218–226. (A)
NP218–226 peptide freshly dissolved in PBS was diluted as indicated in
200 ml of cystine-containing DMEM and incubated for 2 h to produce
CysNP218–226 or incubated in cystine-free DMEM with TCEP as a non-
cysteinylated control. Alternatively, an old stock consisting primarily of
dimeric NP218–226 was treated in cystine-free DMEM in the same manner
in the presence or absence of TCEP. Diluted peptides were then incu-
bated for 1 h at 268C with T2-Kd cells previously cultured for 14 h at
268C and shifted to 378C for 2 h to melt Kd molecules. The cells were
then analyzed by flow cytometry after staining with fluorescein-conju-
gated SF1.1.1 mAb. (B) TCD81 specific for unmodified NP218–226 were
tested in a microcytotoxicity assay for their ability to lyse 51Cr-labeled
P815 target cells incubated in the presence of peptides treated as above. Figure 7. Cysteinylated and dimerized NP218–226 species can be recov-
ered from virus-infected cells. Low-molecular mass, TFA-soluble material
present in lysates from 109 PR8-infected P815 cells (A), 5 3 108 P815
cells spiked with synthetic unmodified NP218–226 (B), and 5 3 108 VV-
NP218–226–infected P815 cells (C and D) were fractionated by RP-HPLC,
and 5 ml of each fraction (1 ml in A; 0.25 ml in B–D) was then added to
low temperature–induced, 51Cr-labeled RMA-S/Kd cells in the presence
(filled symbols) or absence (open symbols) of 200 mM TCEP and tested
for lysis in a microcytotoxicity assay, using TCD81 lines raised to TCEP-
treated (A–C) or cysteinylated NP218–226. TCD81 lines were derived by
four rounds of stimulation of splenocytes from PR8-infected mice with
APCs pulsed with HPLC-purified, unmodified or cysteinylated NP218–226.
Note that B–D show only fractions collected from 24–30 min.1763 Chen et al.
ing to cysteinylated and unmodified NP218–226 were recov-
ered from L929-Kd cells but not L929 cells. Dilution of
peak fractions revealed that expression of Kd resulted in at
least a 25-fold increase in the recovery of NP218–226. This
confirms numerous prior studies demonstrating the MHC
dependence of antigenic peptide recovery (1).
Cysteinylated NP218–226 Is Presented In Vivo. The ultimate
demonstration of the biological relevance of cysteinylated
NP218–226 is that specific TCD81 are elicited in PR8-infected
mice. We could show this by stimulating splenocytes derived
from PR8-infected mice with RP-HPLC–purified, cysteiny-
lated peptide. After three to four rounds of stimulation, we
obtained TCD81 that preferentially recognize cysteinylated
peptide (Fig. 8 A). In the same assay, the noncysteinylated
peptide is preferentially recognized by TCD81 induced in the
standard manner (Fig. 8 B). The recovery of TCD81 specific for
the cysteinylated peptide could not be attributed to in vitro
stimulation of naive TCD81, as we failed to obtain any activity
using splenocytes from nonimmunized mice (data not shown).
Using TCD81 stimulated by the cysteinylated NP218–226, it
was possible to formally demonstrate that the 25-min frac-
tion derived from minigene-expressing cells contained cys-
teinylated peptide (Fig. 7 D). Indeed, now antigenicity was
destroyed by TCEP exposure, in contrast to the enhancing
activity observed with other peptides. We also detected an
additional peak at 24.5 min. This probably represents the
methionine-oxidized form of cysteinylated NP218–226, which,
based on experience with other peptides, often elutes slightly
faster than the nonoxidized form, providing evidence that
this modification occurs in cells.
Discussion
In this paper, we confirm and extend the findings of
Meadows et al. (4) that modification of the SH group of
cysteine-containing peptides has important positive and
negative effects on their antigenicity and immunogenicity
in vitro and in vivo. Failure to consider these effects can
have disastrous consequences for the accurate interpretation
of several different types of experiments.
In our own case, the use of synthetic peptides in the ab-
sence of reducing agents led us to erroneously favor the idea
that the subdominant status of two cysteine-containing pep-
tides was due to a greater number of complexes required for
TCD81 recognition and correlated with the atypical growth of
TCD81 in vitro. In other experiments (our unpublished re-
sults), it also led us to the incorrect quantitation of peptides
recovered from virus-infected cells. A further potential meth-
odological pitfall is that autooxidation of reducing agents can
cause additional artifacts. This can be minimized by inclusion
of a chelating agent, such as DTPA (diethylenetriaminepenta-
acetic acid), with the reducing agent.
These errors are probably widespread. We demonstrate
that two cysteine-containing LCMV determinants restricted
by a different class I molecule are also modified in vitro
through their sulfhydryl groups, with a resulting 10–100-fold
loss in antigenicity. These determinants were the subject of a
recent study (10) focused on the factors involved in the im-
munodominance hierarchy of the determinants. The failure
to add reducing agents during peptide titration probably led
to erroneous calculations of peptides present in virus-infected
cells, particularly because the peptide titration curves were
nearly identical to those we obtained in the absence of reduc-
ing agents. Results obtained in this study with in vivo transfer
of TCD81 lines must also be questioned, as the cells were
propagated in vitro with synthetic peptides in the absence of
reducing agents. In another recent study of the fine specificity
of a TCD81 clone for a cysteine-containing peptide, amino
acids were substituted for cysteine, many of which enhanced
the antigenicity of the peptide (11). Based on our findings,
we would predict that simple reduction of the wild-type pep-
tide would have a similar (or greater) effect.
In addition to reducing antigenicity, modification of cys-
teine can result in the generation of TCD81 specific for the
modified determinant. We show that PR8-infected mice
generate TCD81 that prefer cysteinylated NP218–226. We also
demonstrate that PR8-infected cells generate an SH-modi-
fied peptide that coelutes with cysteinylated NP218–226 and
is recognized by TCD81 specific for cysteinylated NP218–226.
This species almost certainly represents cysteinylated NP218–226,
although definitive evidence requires mass spectroscopy.
The recognition of posttranslationally modified peptides by
TCD81 adds to the already formidable challenge of under-
standing in vivo TCD81 responses but can be ignored only
at the peril of the investigator.
We can only speculate where NP218–226 is cysteinylated
during its processing and presentation by virus-infected
cells. It is theoretically possible that the cystine derives nat-
urally from a disulfide bond present in NP. It is difficult,
though admittedly not impossible, to imagine the pro-
teolytic liberation of cysteinylated NP218–226. Given the
highly reducing environment of the cytosol and nucleus, it
also seems unlikely that cysteinylation would occur before
peptide translocation into the ER. The ER provides a much
more oxidizing environment and possesses resident pro-
teins that catalyze thiol–disulfide interchange, including
protein disulfide isomerase (12). There is evidence that
exogenous homocysteine is added to HLA class I molecules
Figure 8. Cysteinylated NP218–226 is presented in vivo. TCD81 were
produced from PR8-infected mice by stimulation with HPLC-purified,
cysteinylated (A) or unmodified (B) NP218–226. Synthetic NP218–226 was
cysteinylated by dilution into serum-free DME and incubation for 2 h
at room temperature or maintained in unmodified form by addition of
200 mM TCEP. Diluted peptides were then added into assay wells con-
taining TCD81 and 51Cr-labeled P815 targets, and lysis was determined by
microcytotoxicity assay.1764 Cysteine Modification of Viral Peptides
in an early secretory compartment (13). If cysteinylation
occurs in the ER, it may occur before peptide loading onto
class I molecules. Alternatively, cysteinylation could occur
after peptide binding, particularly in the case of NP218–226,
as the SH must be directed away from the groove (so as to
accommodate dimer binding). In this case, it could occur
anywhere from the ER to the cell surface. Cysteine is thought
to be the major reductant in the endosomal pathway, and
although there is no evidence that functional Kd molecules
visit these compartments, this remains a possibility.
It was previously reported that disulfide-linked homo-
dimeric peptides could bind to class I molecules (14). We
provide another example of this and further demonstrate that
this can occur naturally in cells. Recovery of dimers required
expression of NP218–226 as a cytosolic minigene, which results
in at least 10–1,000-fold overproduction of peptide–class I
complexes relative to expression of peptide in its natural con-
text (7, 9), and the extent to which overexpression of peptide
is required remains to be determined. As peptide cross-link-
ing is expected to be a second-order reaction, it implies that
NP218–226 is present at a very high concentration intracellu-
larly. It is hard to imagine this occurring outside of the ER,
and it may occur in the vicinity of TAP, which is required for
transport of NP218–226 into the ER (our unpublished results).
These findings have important clinical implications. First,
for synthetic peptide vaccines (or other exogenous antigen
vaccine preparations with vulnerable cysteine residues in an-
tigenic peptides), modification of the cysteine in vitro or in
vivo can obviously have major negative effects on immuno-
genicity. This can be avoided by modifying the side chain to
a nonreactive form. For NP218–226 and NP39–47, this is
achieved simply by substitution with alanine or serine, which
did not detrimentally affect peptide binding or TCD81 trig-
gering. This strategy will probably work for most peptides.
For others, it is possible that chemical modification of the
SH group (e.g., treatment with an alkylating agent or a
heavy metal) will do the job. Second, if increased cysteinyla-
tion is associated with a disease process, this could lead to au-
toimmune recognition of cysteinylated self peptides.
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